

Charge the fee of \$9 for the one additional claim in excess of 20 and the fee of \$42 for the one additional independent claim added herewith to deposit account No. 25-0120.

REMARKS

Responsive to the restriction requirement set forth in the outstanding Official Action, applicants hereby provisionally elect Group IV, claim 18, with partial traverse.

As regards the claims as filed, it is believed that Group VII, claims 23 and 24, should plainly be examined together with claim 18. We note in this regard that the restriction requirement set forth in the outstanding Official Action did not contend that Group VII is patentably distinct relative to Group IV. Furthermore, we note that any complete search for the subject matter of claim 18 would necessarily also involve searching for the subject matter of claims 23 and 24, such that it is believed to be appropriate for those claims to be examined together with claim 18.

In a similar vein, the dependency of claims 19, 20 and 26-29 (which originally were multiply dependent) is modified by the present amendment, consistent with applicants' election, such that claims 19, 20 and 26-29 may also be properly examined together with claim 18.

Lastly, a new claim 34 is added, which is identical to present claim 25, but which recites anti-DAF antibodies, and

which claim may also be properly examined with claims 18-20, 23, 24 and 26-29.

Therefore, it is believed that the application should receive an action on the merits of claims 18-20, 23, 24, 26-29 and 34. Such action is respectfully requested.

Responsive to the requirement for submission of a substitute Sequence Listing, a substitute Sequence Listing has been prepared in paper and disk formats, and is attached to the present response. Applicants hereby state that the content of the attached paper and disk formats is the same, and that these introduce no new matter into the present application.

The Official Action also observed that the description of Figure 2 appeared to be missing a sequence identification number for the nucleic acid sequence. Page 12 of the specification has been revised to improve the clarity of the description on this point. Note that Sequence ID NO:2 refers to the nucleic acid sequence, whereas Sequence ID NO:1 corresponds to the predicted amino acid sequence. The modification to page 12 of the specification is believed to eliminate any potential confusion as to that point.

In view of the present amendment and the foregoing Remarks, therefore, it is believed that this application is now in condition for action on the merits, and such action is accordingly respectfully requested.

MORGAN et al. S.N. 09/673,032

Attached hereto is a marked-up version of the changes made to the specification and claims. The attached page is captioned "VERSION WITH MARKINGS TO SHOW CHANGES MADE."

Respectfully submitted,

YOUNG & THOMPSON

*Thomas W. Patch*  
THOMAS W. PATCH 3027

By *for*

Andrew J. Patch  
Attorney for Applicants  
Registration No. 32,925.  
745 South 23rd Street  
Arlington, VA 22202  
Telephone: 521-2297

March 28, 2002



MORGAN et al. S.N. 09/673,032

RECEIVED

APR 03 2002

TECH CENTER 1600/2900

VERSION 1.0 MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

Paragraph beginning at line 22 of page 12 has been amended as follows:

Figure 2 is the nucleotide (SEQ ID NO: 2) and deduced amino acid (SEQ ID NO: 1) sequence of pig CD59 [(SEQ ID NO:2)]. The numbers below refer to the nucleotide sequence, the numbers on the right refer to the amino acid sequence. The first residue of the mature protein (L-1) is boxed. Potential N-glycosylation sites (N-X-S/T) are denoted by psi ( $\Psi$ ). The arrow ( $\downarrow$ ) indicates the putative GPI-anchor addition site (S-73). The pig CD59 GenBank accession number is AF020302.

IN THE CLAIMS:

Claim 19 has been amended as follows:

19. (twice amended) An RNA molecule comprising an RNA sequence corresponding to a DNA sequence according to Claim [17] 18.

Claim 20 has been amended as follows:

20. (twice amended) A nucleic acid probe having a sequence according to claim [17] 19, and optionally including a label.

MORGAN et al. S.N. 09/673,032

Claim 26 has been amended as follows:

26. (twice amended) A vector comprising the nucleic acid sequence of claim [17] 19.

Claim 29 has been amended as follows:

29. (twice amended) A non-human transgenic animal wherein the transgene comprises the DNA of Claim [17] 18.